Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma
NCT07707973Phase 2Not yet recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Jul 2026
- Primary completion
- Jan 2028
01
Overview
A Phase 2 trial of nimotuzumab in glioblastoma (GBM), sponsored by Tianjin First Central Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07707973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07707973.